Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

FDA Approves Combo Painkiller from OxyContin Maker

July 24, 2014 2:59 pm | News | Comments

The Food and Drug Administration has approved a new combination pain pill from the maker of OxyContin that is designed to discourage abuse by painkiller addicts. Read more...                     

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Metastatic Brain Tumor Treatment Could Be on the Horizon

July 24, 2014 3:19 pm | News | Comments

Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases. However, a new study provides hope that previously studied SapC-DOPS could be used for treatment of brain cancer that has spread. Read more...

TOPICS:

Researchers Create Vaccine for Dust-Mite Allergies

July 24, 2014 3:05 pm | News | Comments

If you’re allergic to dust mites (and chances are you are), help may be on the way. Researchers have developed a vaccine that can combat dust-mite allergies by naturally switching the body’s immune response. Read more...         

TOPICS:

Merck Kicks Off Phase 3 Study of CMV Antiviral

July 24, 2014 11:18 am | News | Comments

Merck announced that the first patient has been enrolled in a global Phase 3 clinical study that will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. Read more...

TOPICS:
Advertisement

BMS, Ono Collaborate on Immuno-Oncology

July 24, 2014 11:13 am | News | Comments

Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. Read more...

TOPICS:

Research Shows that One CF Drug Counteracts Another

July 24, 2014 11:08 am | News | Comments

In lab experiments using tissue samples cultured from cystic fibrosis patients, scientists at the UNC School of Medicine and the UNC Marsico Lung Institute have shown that a new CF drug counteracts the intended beneficial molecular effect of another CF drug. Read more...

TOPICS:

Gilead, MPP Partner on Access to HIV, Hep C Drug

July 24, 2014 10:56 am | News | Comments

Gilead Sciences Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval. Read more...

TOPICS:

TCGA Identifies Four Stomach Cancer Subtypes

July 24, 2014 10:51 am | News | Comments

Stomach cancers fall into four distinct molecular subtypes researchers with The Cancer Genome Atlas (TCGA) Network have found: a discovery that could change how researchers think about developing treatments for stomach cancer, also called gastric cancers or gastric adenocarcinomas. Read more...

TOPICS:

Developing Multi-Functional Anti-Inflammatory Drugs

July 24, 2014 10:44 am | by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics | Articles | Comments

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...

TOPICS:
Advertisement

FDA Approves Malignant Hyperthermia Drug

July 23, 2014 2:57 pm | News | Comments

Eagle Pharmaceuticals Inc. announced that the FDA has approved Ryanodex (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia, along with the appropriate supportive measures. Read more...      

TOPICS:

Inovio's HPV Immunotherapy Hits Primary Endpoint

July 23, 2014 2:35 pm | News | Comments

Inovio Pharmaceuticals Inc. announced successful results from Phase 2 trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Read more...         

TOPICS:

Oral Cancer Drug May be Potential Alzheimer’s Therapy

July 23, 2014 2:26 pm | News | Comments

Scientists are now reporting new progress on a set of compounds, initially developed for cancer treatment, that shows promise as a potential oral therapy for Alzheimer’s. Read more...                    

TOPICS:

Head of Troubled CDC Anthrax Lab Resigns

July 23, 2014 2:09 pm | News | Comments

The head of the government lab which potentially exposed workers to live anthrax has resigned, an agency spokesman said Wednesday. Michael Farrell was head of the Centers for Disease Control and Prevention lab since 2009. He submitted his resignation Tuesday, the spokesman said. Read more...

TOPICS:

Survey Finds Sharp Increase in Teen HGH Use

July 23, 2014 1:31 pm | by David Crary, AP National Writer | News | Comments

Experimentation with human growth hormones by America's teens more than doubled in the past year, as more young people looked to drugs to boost their athletic performance and improve their looks, according to a new survey. Read more...     

TOPICS:

FDA Approves Gilead's Zydelig for Three Cancers

July 23, 2014 1:13 pm | News | Comments

The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma. Read more...            

TOPICS:

Neurotrophic Keratitis Drug Gets Orphan Drug Designation

July 23, 2014 11:26 am | News | Comments

Dompe, a leader in R&D for new therapeutic solutions for the treatment of rare diseases, announced that rhNGF (Recombinant Human Nerve Growth Factor) has been designated as an orphan drug by the American Food and Drug Administration. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading